Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
Heidelberg Pharma AG today announced that they will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences. Heidelberg Pharma uses Amanitin as an innovative toxin to develop new cancer therapies that, when coupled to an antibody, can specifically kill even dormant cancer cells and overcome resistance. The candidate HDP-101 is about to enter clinical development for the treatment of multiple myeloma.